(1)
-
On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials
-
Novel vaccine candidate offers viable alternative to antibiotics, thereby strategically aligned with REPAIR Impact Fund s mission to combat antimicrobial resistance (AMR)
-
-
Group B Streptococcus (GBS) is one of the leading causes of stillbirth and infant mortality representing a significant unmet need globally, including in the US and Europe; nearly one in five women globally are colonized by GBS
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ Today, the Novo Holdings REPAIR Impact Fund announces a further investment in MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), renewing its commitment to the company following two tranches of investment in 2018 and 2019. Initi